CJC-1295 with DAC
Also known as CJC-1295 DAC · DAC:GRF · CJC-1295 with Drug Affinity Complex · Nε30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-GRF(1-29)-Lys30
In receptor-signaling terms, the GRF(1-29) backbone of this molecule is a ligand for the growth-hormone-releasing-hormone receptor (GHRHR), a class-B secretin-family G-protein-coupled receptor expressed on pituitary somatotroph cells.
The overview
What is CJC-1295 with DAC?
In receptor-signaling terms, the GRF(1-29) backbone of this molecule is a ligand for the growth-hormone-releasing-hormone receptor (GHRHR), a class-B secretin-family G-protein-coupled receptor expressed on pituitary somatotroph cells. Ligand binding promotes coupling to the stimulatory Gs protein, activating adenylate cyclase and raising intracellular cyclic AMP; cAMP activates protein kinase A, which phosphorylates the CREB transcription factor and, with Pit-1, modulates growth-hormone gene transcription, alongside increased intracellular calcium. The four backbone substitutions (D-Ala2, Gln8, Ala15, Leu27) reduce susceptibility to dipeptidyl-peptidase-IV and other proteolytic cleavage in vitro. The distinguishing "DAC" feature is an Nε-maleimidopropionyl linker on a C-terminal Lys30: the maleimide reacts selectively with the free thiol of cysteine-34 on serum albumin, forming a stable thioether bioconjugate (1:1 loading). This albumin tethering is the basis for the molecule's extended plasma residence in pharmacokinetic studies. All statements here describe in-vitro receptor coupling and conjugation chemistry, not clinical outcomes.
In the research
Where CJC-1295 with DAC shows up
The areas researchers focus on with CJC-1295 with DAC - and why it has the science community paying attention.
- GHRHR (class-B GPCR) receptor-binding and Gs/adenylate-cyclase/cAMP signaling assays
- Somatotroph cAMP/PKA/CREB pathway and GH-gene transcription models in vitro
- Maleimide-to-albumin-Cys34 site-selective bioconjugation chemistry
- Peptide proteolytic-stability / DPP-IV-resistance characterization
- Albumin-binding (DAC) half-life-extension platform pharmacokinetics
- Pulsatility of secretagogue-driven hormone release in physiological models
By the numbers
The facts that matter
To the molecule
Molecular specifications
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys (30 residues; backbone = GRF(1-29) with substitutions D-Ala2, Gln8, Ala15, Leu27, plus a C-terminal Lys30 bearing an Nε-maleimidopropionyl DAC linker). One-letter core (substitutions noted): Y-[D-A]-DAIFT-Q-SYRKVL-A-QLSARKLL-QDI-L-SR-KSourced, not claimed
The science behind it
The peer-reviewed studies behind CJC-1295 with DAC, linked so you can read them yourself.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of Clinical Endocrinology & Metabolism.
“The estimated half-life of CJC-1295 was 5.8-8.1 d, and dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more were observed.”
- Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog The Journal of Clinical Endocrinology & Metabolism.
“GH secretion was increased after CJC-1295 administration with preserved pulsatility (paraphrase; abstract confirms pulsatility preserved, ~7.5-fold trough GH rise, ~45% IGF-I increase).”
- Léger R, Thibaudeau K, Robitaille M, Quraishi O, van Wyk P, Bousquet-Gagnon N, Carette J, Castaigne JP, Bridon DP (2004). Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog Bioorganic & Medicinal Chemistry Letters.
“GLP-1 derivatives containing a maleimidopropylamido linker were bioconjugated to Cys34 of human serum albumin (HSA) (paraphrase; abstract confirms maleimidopropyl linker conjugated to Cys34 of HSA, DPP-IV stabilization, and CJC-1131 as best analog).”
- Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV (2025). Growth hormone-releasing hormone receptor (GHRH-R) and its signaling Reviews in Endocrine and Metabolic Disorders.
“Splice variant 1 (SV1) possesses the greatest similarity to the full-length GHRH-R and remains functional by eliciting cAMP signaling and mitogenic activity upon stimulation by GHRH. (NOTE: the draft's quoted sentence naming 'adenylate cyclase' and 'protein kinase A' is NOT in the public abstract and could not be verified verbatim; replaced with the verifiable abstract sentence on cAMP signaling.)”
- Frohman LA, Downs TR, Chomczynski P (1992). Regulation of growth hormone secretion Frontiers in Neuroendocrinology.
“The adenylate cyclase-cyclic AMP-protein kinase A system appears to exert a predominant role in the signal transduction of GHRH-stimulated GH secretion. (CORRECTED PMID: draft listed 1361458 which is an unrelated Neuropeptide Y/LH paper; real paper is PMID 1360911, Front Neuroendocrinol 1992;13(4):344-405.)”
Straight answers
Questions, answered
Is CJC-1295 with DAC approved by the FDA?
No. CJC-1295 with DAC is not an FDA-approved drug. We supply it as a research-use-only reference compound, identity-verified for purity with a COA on every vial.
What class of compound is CJC-1295 with DAC?
CJC-1295 with DAC is classified as: Synthetic growth-hormone-releasing hormone (GHRH/GRF) analog; albumin-binding ("Drug Affinity Complex", DAC) long-acting secretagogue peptide.
What is the molecular weight of CJC-1295 with DAC?
The molecular weight of CJC-1295 with DAC is ~3647 g/mol (free pre-conjugation DAC peptide; vendor MW commonly cited ~3647.8 g/mol). After covalent conjugation to ~66.5 kDa human serum albumin the effective circulating mass is ~70 kDa., with a molecular formula of C165H269N47O46 (PubChem CID 91971820 for the maleimidopropionyl-Lys30 DAC molecule; some vendor sources list C165H271N47O46. Formula listings vary across non-authoritative vendors - PubChem value reported as primary.).
What is the CAS number for CJC-1295 with DAC?
The CAS Registry Number for CJC-1295 with DAC is 863288-34-0.
What is the amino acid sequence of CJC-1295 with DAC?
CJC-1295 with DAC has the sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys (30 residues; backbone = GRF(1-29) with substitutions D-Ala2, Gln8, Ala15, Leu27, plus a C-terminal Lys30 bearing an Nε-maleimidopropionyl DAC linker). One-letter core (substitutions noted): Y-[D-A]-DAIFT-Q-SYRKVL-A-QLSARKLL-QDI-L-SR-K.
Go deeper
More on CJC-1295 with DAC
Keep exploring
Related peptides
For in-vitro laboratory research use only. Not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. CJC-1295 with DAC is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.